There is considerable interest in developing biomarkers to detect the earliest stages of Alzheimer’s disease, well prior to symptoms. To the degree that Alzheimer’s is a lifestyle condition, it might be postponed or averted if discovered early on. To the degree that it is not a lifestyle condition, then the first viable anti-amyloid immunotherapies offer some chance, the odds yet to be determined, of averting Alzheimer’s in the earliest stages. Some progress has been made on predictive biomarkers that can be <a href="https://www.fightaging.org/archives/2022/07/detecting-alzheimers-disease-seventeen-years-in-adva…
miR-519a-3p as a Circulating Marker for Early Alzheimer's Disease
There is considerable interest in developing biomarkers to detect the earliest stages of Alzheimer’s disease, well prior to symptoms. To the degree that Alzheimer’s is a lifestyle condition, it might be postponed or averted if discovered early on. To the degree that it is not a lifestyle condition, then the first viable anti-amyloid immunotherapies offer some chance, the odds yet to be determined, of averting Alzheimer’s in the earliest stages. Some progress has been made on predictive biomarkers that can be <a href="https://www.fightaging.org/archives/2022/07/detecting-alzheimers-disease-seventeen-years-in-adva…